Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Eikon Therapeutics Inc.
Sponsor

Eikon Therapeutics Inc.

United States 3 2nd Street Floor 4, 07311-4045, United States

About the sponsor

Eikon Therapeutics Inc. focuses on advanced solid tumors through early-stage oncology programs that assess novel agents as single therapies and in combination with established anti-cancer agents. The portfolio includes interest in treatment-resistant disease settings and tumor control across a broad range of solid malignancies.

  • Solid Tumor Oncology
  • Monotherapy Development
  • Combination Cancer Therapy
  • Treatment-Resistant Disease

Research activity also includes MSI-H tumors, reflecting attention to molecularly defined subsets within advanced disease.

About Specializations

Eikon Therapeutics Inc. runs clinical trials in conditions such as Neoplasm, Non-small cell lung cancer stage IV, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Non-small cell lung cancer stage IV

Recruiting

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Neoplasm

Recruiting

Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Eikon Therapeutics Inc.

Neoplasm

Recruiting

Study of IMP1734, Paclitaxel, and Abiraterone for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Eikon Therapeutics Inc.

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Recruiting
Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.